<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <title>GLP-1 Drugs Side Effects Legal Support | Expert Legal Representation</title>
  <!-- Google fonts for professional look -->
  <link href="https://fonts.googleapis.com/css2?family=Inter:wght@300;400;500;600;700&display=swap" rel="stylesheet">
  <style>
    /* Reset and base styles */
    *, *::before, *::after {
      box-sizing: border-box;
      margin: 0;
      padding: 0;
    }

    body {
      font-family: 'Inter', -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;
      line-height: 1.6;
      color: #1a202c;
      background-color: #ffffff;
      font-size: 16px;
    }

    /* Fixed phone number bar */
    .phone-bar {
      background: #dc2626;
      color: #fff;
      text-align: center;
      padding: 0.75rem;
      position: fixed;
      top: 0;
      left: 0;
      right: 0;
      z-index: 1000;
      font-weight: 600;
      font-size: 1.1rem;
    }

    .phone-bar a {
      color: #fff;
      text-decoration: none;
    }

    .phone-bar a:hover {
      text-decoration: underline;
    }

    /* Header styles */
    .main-header {
      background: linear-gradient(135deg, #ffffff 0%, #f8fafc 100%);
      color: #1e3a8a;
      margin-top: 3.5rem;
      position: relative;
      overflow: hidden;
      padding: 6rem 0 4rem 0;
      border-bottom: 3px solid #1e40af;
    }

    .main-header::before {
      content: '';
      position: absolute;
      top: 0;
      left: 0;
      right: 0;
      bottom: 0;
      background: linear-gradient(45deg, transparent 30%, rgba(30, 64, 175, 0.03) 50%, transparent 70%);
    }

    .top-nav {
      background: #1e40af;
      color: white;
      padding: 1rem 0;
      text-align: center;
      font-weight: 600;
      font-size: 0.875rem;
      letter-spacing: 0.5px;
    }

    .hero-section {
      padding: 2rem 0;
    }

    .header-content {
      max-width: 1200px;
      margin: 0 auto;
      padding: 0 2rem;
      display: grid;
      grid-template-columns: 1.2fr 1fr;
      gap: 4rem;
      align-items: center;
    }

    .text-content {
      text-align: center;
    }

    .text-content h1 {
      font-size: 3.25rem;
      font-weight: 900;
      margin-bottom: 2rem;
      line-height: 1.1;
      color: #1e3a8a;
      position: relative;
      display: inline-block;
      font-family: 'Inter', -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;
      letter-spacing: -0.02em;
    }

    .text-content h1::after {
      content: '';
      position: absolute;
      bottom: -12px;
      left: 0;
      width: 100%;
      height: 4px;
      background: linear-gradient(90deg, #dc2626 0%, #b91c1c 100%);
      border-radius: 2px;
    }

    .text-content .subtitle {
      font-size: 1.125rem;
      margin: 2.5rem 0 3rem 0;
      color: #4b5563;
      line-height: 1.7;
      font-weight: 400;
      max-width: 550px;
      margin-left: auto;
      margin-right: auto;
    }

    .text-content .content-section {
      text-align: center;
      margin-top: 3rem;
    }

    .header-stats {
      display: flex;
      gap: 2.5rem;
      margin: 3rem 0 0 0;
      justify-content: center;
    }

    .stat-item {
      display: flex;
      flex-direction: column;
      align-items: center;
      text-align: center;
      background: #ffffff;
      padding: 2rem 1.5rem;
      border-radius: 16px;
      border: 1px solid #e5e7eb;
      min-width: 160px;
      box-shadow: 0 4px 6px rgba(0, 0, 0, 0.05);
      transition: all 0.3s ease;
    }

    .stat-item:hover {
      transform: translateY(-2px);
      box-shadow: 0 8px 25px rgba(0, 0, 0, 0.1);
    }

    .stat-number {
      font-size: 2.75rem;
      font-weight: 900;
      color: #dc2626;
      margin-bottom: 0.75rem;
      position: relative;
      line-height: 1;
    }

    .stat-number::after {
      content: '';
      position: absolute;
      bottom: -10px;
      left: 50%;
      transform: translateX(-50%);
      width: 50px;
      height: 3px;
      background: #dc2626;
      border-radius: 2px;
    }

    .stat-label {
      font-size: 0.875rem;
      color: #6b7280;
      margin-top: 0.75rem;
      font-weight: 600;
      letter-spacing: 0.5px;
    }

    .cta-container {
      background: #ffffff;
      padding: 2.5rem;
      border-radius: 20px;
      border: 1px solid #e5e7eb;
      position: relative;
      box-shadow: 0 8px 32px rgba(0, 0, 0, 0.08);
      transition: all 0.3s ease;
    }

    .cta-container:hover {
      transform: translateY(-2px);
      box-shadow: 0 12px 40px rgba(0, 0, 0, 0.12);
    }

    .primary-cta {
      display: block;
      background: linear-gradient(135deg, #dc2626 0%, #b91c1c 100%);
      color: white;
      text-decoration: none;
      padding: 1.25rem 2rem;
      border-radius: 12px;
      font-size: 1.125rem;
      font-weight: 700;
      text-align: center;
      transition: all 0.3s ease;
      margin-bottom: 1.5rem;
      width: 100%;
      box-shadow: 0 4px 12px rgba(220, 38, 38, 0.2);
      letter-spacing: 0.5px;
    }

    .primary-cta:hover {
      background: linear-gradient(135deg, #b91c1c 0%, #991b1b 100%);
      transform: translateY(-2px);
      box-shadow: 0 8px 25px rgba(220, 38, 38, 0.3);
    }

    .cta-note {
      text-align: center;
      font-size: 0.875rem;
      color: #6b7280;
      margin-bottom: 1.5rem;
      font-weight: 500;
      line-height: 1.5;
    }

    .trust-badges {
      display: flex;
      flex-direction: column;
      gap: 0.75rem;
    }

    .badge {
      color: #374151;
      font-size: 0.875rem;
      font-weight: 500;
      display: flex;
      align-items: center;
      gap: 0.75rem;
      padding: 0.5rem 0;
    }

    .badge::before {
      content: '✓';
      color: #22c55e;
      font-weight: bold;
      font-size: 1.125rem;
    }

    @media (max-width: 1024px) {
      .header-content {
        grid-template-columns: 1fr;
        gap: 3rem;
        align-items: center;
      }

      .text-content {
        text-align: center;
      }

      .text-content .content-section {
        text-align: center;
      }

      .header-stats {
        justify-content: center;
      }

      .text-content h1 {
        font-size: 2.75rem;
      }

      .text-content h1::after {
        width: 100%;
      }

      .text-content .subtitle {
        font-size: 1.125rem;
        max-width: 600px;
      }

      .header-stats {
        justify-content: center;
        flex-wrap: wrap;
        gap: 2rem;
      }

      .stat-item {
        min-width: 140px;
      }

      .cta-container {
        max-width: 400px;
        margin: 0 auto;
      }

      .mdl-content {
        grid-template-columns: 1fr;
        gap: 2rem;
      }

      .effects-categories {
        grid-template-columns: 1fr;
        gap: 2rem;
      }

      .action-steps {
        grid-template-columns: 1fr;
      }
    }

    @media (max-width: 768px) {
      .hero-section {
        padding: 2rem 0;
      }

      .text-content h1 {
        font-size: 2rem;
      }

      .text-content h1::after {
        width: 100%;
      }

      .header-stats {
        flex-direction: column;
        gap: 1rem;
        justify-content: center;
      }

      .text-content h1::after {
        left: 50%;
        transform: translateX(-50%);
      }

      .stat-item {
        min-width: auto;
        width: 100%;
      }

      .cta-container {
        padding: 1.5rem;
      }

      .trust-badges {
        gap: 0.25rem;
      }

      .badge {
        font-size: 0.8rem;
      }

      .mdl-header h2 {
        font-size: 1.75rem;
      }

      .mdl-subtitle {
        font-size: 1rem;
      }

      .effect-category {
        padding: 1.5rem;
      }

      .action-step {
        padding: 1.25rem;
      }

      .eligibility-button {
        padding: 0.875rem 1.5rem;
        font-size: 1rem;
      }

      .urgent-notice {
        padding: 1.5rem;
      }
    }

    /* Sticky Navigation */
    .sticky-nav {
      position: sticky;
      top: 3.5rem;
      z-index: 1000;
      background: rgba(255, 255, 255, 0.98);
      backdrop-filter: blur(10px);
      border-bottom: 2px solid #e5e7eb;
      box-shadow: 0 2px 8px rgba(0, 0, 0, 0.08);
    }

    .nav-wrapper {
      max-width: 1200px;
      margin: 0 auto;
      padding: 0.75rem 2rem;
    }

    .nav-container {
      display: flex;
      justify-content: space-between;
      align-items: center;
    }

    .nav-links {
      display: flex;
      gap: 2rem;
    }

    .nav-links a {
      color: #1e3a8a;
      text-decoration: none;
      font-weight: 500;
      transition: color 0.3s ease;
    }

    .nav-links a:hover {
      color: #1e40af;
    }

    .nav-cta {
      background: #dc2626;
      color: white;
      padding: 0.75rem 1.5rem;
      border-radius: 0.5rem;
      font-weight: 600;
      text-decoration: none;
      transition: all 0.3s ease;
    }

    .nav-cta:hover {
      background: #b91c1c;
      transform: translateY(-1px);
    }

    /* Floating Form */
    .floating-form {
      position: fixed;
      right: 0;
      top: 50%;
      transform: translateY(-50%) translateX(100%);
      width: 350px;
      background: white;
      border-radius: 16px 0 0 16px;
      box-shadow: 0 8px 32px rgba(0, 0, 0, 0.15);
      z-index: 900;
      transition: all 0.5s ease;
      border: 1px solid rgba(0, 0, 0, 0.1);
      border-right: none;
      opacity: 0;
      pointer-events: none;
    }

    .floating-form.visible {
      opacity: 1;
      pointer-events: all;
      transform: translateY(-50%) translateX(0);
    }

    .floating-form .form-content {
      opacity: 1;
    }

    .form-header {
      display: flex;
      justify-content: space-between;
      align-items: center;
      padding: 1rem;
      background: #1e3a8a;
      color: white;
      border-radius: 16px 0 0 0;
    }

    .form-header h3 {
      margin: 0;
      font-size: 1rem;
    }



    .form-content {
      padding: 1.5rem;
    }

    .form-intro {
      font-size: 0.875rem;
      color: #4a5568;
      margin-bottom: 1.5rem;
      text-align: center;
      font-weight: 500;
    }

    .floating-form .form-group {
      margin-bottom: 1.25rem;
    }

    .floating-form select {
      width: 100%;
      padding: 0.875rem;
      border: 1px solid #e2e8f0;
      border-radius: 0.5rem;
      font-size: 0.875rem;
      color: #1a202c;
      background: white;
      transition: border-color 0.3s ease;
    }

    .floating-form select:focus {
      outline: none;
      border-color: #1e40af;
      box-shadow: 0 0 0 3px rgba(30, 64, 175, 0.1);
    }

    .floating-cta {
      width: 100%;
      background: #dc2626;
      color: white;
      border: none;
      padding: 1rem;
      border-radius: 0.5rem;
      font-weight: 600;
      font-size: 1rem;
      cursor: pointer;
      transition: all 0.3s ease;
      margin-bottom: 1rem;
    }

    .floating-cta:hover {
      background: #b91c1c;
      transform: translateY(-1px);
    }

    .form-note {
      font-size: 0.75rem;
      color: #6b7280;
      text-align: center;
      margin-top: 0.75rem;
      font-weight: 500;
    }

    @media (max-width: 1400px) {
      .floating-form {
        width: 320px;
      }
    }

    @media (max-width: 1024px) {
      .floating-form {
        width: 300px;
      }
    }

    @media (max-width: 768px) {
      .floating-form {
        width: 280px;
      }
    }

    @media (max-width: 480px) {
      .floating-form {
        display: none;
      }
    }

    .nav-container {
      max-width: 1200px;
      margin: 0 auto;
      padding: 0 2rem;
      display: flex;
      justify-content: center;
      gap: 2rem;
      flex-wrap: wrap;
      align-items: center;
    }

    .cta-button {
      background: #dc2626;
      color: white;
      padding: 0.75rem 1.5rem;
      border-radius: 0.5rem;
      font-weight: 600;
      text-decoration: none;
      transition: background-color 0.3s;
    }

    .cta-button:hover {
      background: #b91c1c;
    }

    nav a {
      color: #475569;
      text-decoration: none;
      font-weight: 500;
      padding: 0.5rem 1rem;
      border-radius: 6px;
      transition: all 0.2s ease;
      white-space: nowrap;
    }

    nav a:hover {
      background: #e2e8f0;
      color: #1e40af;
    }

    /* Main content */
    main {
      max-width: 1200px;
      margin: 0 auto;
      padding: 3rem 2rem;
    }

    /* Section styles */
    section {
      margin-bottom: 4rem;
    }

    section h2 {
      font-size: 2rem;
      font-weight: 600;
      margin-bottom: 1.5rem;
      color: #1e3a8a;
      position: relative;
      padding-bottom: 0.5rem;
    }

    section h2::after {
      content: '';
      position: absolute;
      bottom: 0;
      left: 0;
      width: 60px;
      height: 3px;
      background: #1e40af;
      border-radius: 2px;
    }

    /* MDL Section Styles */
    .mdl-section {
      background: linear-gradient(135deg, #f8fafc 0%, #e2e8f0 100%);
      padding: 3rem 0;
      margin: 3rem 0;
      border-radius: 16px;
    }

    .mdl-container {
      max-width: 1200px;
      margin: 0 auto;
      padding: 0 2rem;
    }

    .mdl-header {
      text-align: center;
      margin-bottom: 2.5rem;
    }

    .mdl-header h2 {
      font-size: 2.25rem;
      color: #1e3a8a;
      margin-bottom: 1rem;
    }

    .mdl-subtitle {
      font-size: 1.125rem;
      color: #4b5563;
      line-height: 1.6;
      max-width: 800px;
      margin: 0 auto;
    }

    .mdl-content {
      display: grid;
      grid-template-columns: 1fr 1fr;
      gap: 3rem;
      align-items: start;
    }

    .mdl-allegations h3 {
      font-size: 1.25rem;
      color: #1e3a8a;
      margin-bottom: 1rem;
      font-weight: 600;
    }

    .mdl-allegations ul {
      list-style: none;
      padding: 0;
    }

    .mdl-allegations li {
      padding: 0.75rem 0;
      border-bottom: 1px solid #e5e7eb;
      color: #374151;
      font-size: 1rem;
      line-height: 1.5;
    }

    .mdl-allegations li:before {
      content: '•';
      color: #dc2626;
      font-weight: bold;
      margin-right: 0.5rem;
    }

    .mdl-status p {
      font-size: 1.125rem;
      color: #374151;
      line-height: 1.6;
      margin-bottom: 1.5rem;
    }

    .warning-box {
      background: #fef3c7;
      border: 1px solid #f59e0b;
      border-radius: 12px;
      padding: 1.5rem;
      margin-top: 1.5rem;
    }

    .warning-box p {
      color: #92400e;
      font-size: 1rem;
      margin: 0;
      line-height: 1.5;
    }

    /* Effects Categories */
    .effects-categories {
      display: grid;
      grid-template-columns: 1fr 1fr;
      gap: 3rem;
      margin: 2rem 0 3rem 0;
    }

    .effect-category {
      background: white;
      padding: 2rem;
      border-radius: 16px;
      box-shadow: 0 4px 6px rgba(0, 0, 0, 0.05);
      border: 1px solid #e5e7eb;
    }

    .effect-category h3 {
      color: #1e3a8a;
      font-size: 1.25rem;
      margin-bottom: 1rem;
      font-weight: 600;
    }

    .effect-list {
      list-style: none;
      padding: 0;
    }

    .effect-list li {
      padding: 0.5rem 0;
      color: #374151;
      font-size: 1rem;
      line-height: 1.5;
      border-bottom: 1px solid #f3f4f6;
    }

    .effect-list li:before {
      content: '•';
      color: #dc2626;
      font-weight: bold;
      margin-right: 0.5rem;
    }

    /* Action Steps */
    .action-steps {
      display: grid;
      grid-template-columns: repeat(auto-fit, minmax(300px, 1fr));
      gap: 2rem;
      margin: 2rem 0;
    }

    .action-step {
      background: white;
      padding: 1.5rem;
      border-radius: 12px;
      box-shadow: 0 2px 4px rgba(0, 0, 0, 0.05);
      border: 1px solid #e5e7eb;
    }

    .step-content h4 {
      color: #1e3a8a;
      font-size: 1.125rem;
      margin-bottom: 0.5rem;
      font-weight: 600;
    }

    .step-content p {
      color: #6b7280;
      font-size: 0.875rem;
      line-height: 1.5;
      margin: 0;
    }

    .urgent-notice {
      background: #ffffff;
      border: 1px solid #e5e7eb;
      border-radius: 12px;
      padding: 2rem;
      margin-top: 2rem;
      text-align: center;
      box-shadow: 0 4px 12px rgba(0, 0, 0, 0.08);
    }

    .urgent-notice p {
      color: #dc2626;
      font-size: 1.25rem;
      margin: 0 0 1.5rem 0;
      font-weight: 700;
      line-height: 1.4;
    }

    .eligibility-cta {
      text-align: center;
      margin-top: 1.5rem;
    }

    .eligibility-button {
      display: inline-block;
      background: linear-gradient(135deg, #dc2626 0%, #b91c1c 100%);
      color: white;
      text-decoration: none;
      padding: 1rem 2rem;
      border-radius: 12px;
      font-size: 1.125rem;
      font-weight: 700;
      transition: all 0.3s ease;
      box-shadow: 0 4px 12px rgba(220, 38, 38, 0.2);
      letter-spacing: 0.5px;
      margin-bottom: 0.75rem;
    }

    .eligibility-button:hover {
      background: linear-gradient(135deg, #b91c1c 0%, #991b1b 100%);
      transform: translateY(-2px);
      box-shadow: 0 8px 25px rgba(220, 38, 38, 0.3);
    }

    .cta-subtitle {
      color: #6b7280;
      font-size: 0.875rem;
      margin: 0;
      font-weight: 500;
    }

    /* Hero section */
    .hero-section {
      background: linear-gradient(135deg, #f8fafc 0%, #e2e8f0 100%);
      padding: 3rem 2rem;
      border-radius: 12px;
      margin-bottom: 3rem;
      text-align: center;
    }

    .hero-section h2 {
      font-size: 2.5rem;
      color: #1e3a8a;
      margin-bottom: 1rem;
    }

    .hero-section p {
      font-size: 1.2rem;
      color: #64748b;
      max-width: 800px;
      margin: 0 auto;
    }

    .hero-cta {
      margin-top: 2rem;
      text-align: center;
    }

    .hero-cta .cta-button {
      font-size: 1.25rem;
      padding: 1rem 2rem;
      margin-bottom: 1rem;
      display: inline-block;
    }

    .hero-cta .cta-note {
      font-size: 1rem;
      color: #64748b;
      margin-top: 0.5rem;
    }

    /* Stats grid */
    .stats-grid {
      display: grid;
      grid-template-columns: repeat(auto-fit, minmax(250px, 1fr));
      gap: 2rem;
      margin: 3rem 0;
    }

    .stat-card {
      background: #fff;
      padding: 2rem;
      border-radius: 12px;
      text-align: center;
      box-shadow: 0 4px 12px rgba(0,0,0,0.05);
      border: 1px solid #e2e8f0;
    }

    .stat-number {
      font-size: 2.5rem;
      font-weight: 700;
      color: #dc2626;
      margin-bottom: 0.5rem;
    }

    .stat-label {
      font-size: 1rem;
      color: #64748b;
      font-weight: 500;
    }

    /* News section */
    .news-grid {
      display: grid;
      grid-template-columns: repeat(auto-fit, minmax(350px, 1fr));
      gap: 2rem;
      margin-top: 2rem;
    }

    .news-card {
      background: #fff;
      border: 1px solid #e2e8f0;
      border-radius: 12px;
      padding: 1.5rem;
      box-shadow: 0 2px 8px rgba(0,0,0,0.05);
      transition: transform 0.2s ease, box-shadow 0.2s ease;
    }

    .news-card:hover {
      transform: translateY(-2px);
      box-shadow: 0 4px 16px rgba(0,0,0,0.1);
    }

    .news-card h3 {
      font-size: 1.25rem;
      font-weight: 600;
      margin-bottom: 0.75rem;
      line-height: 1.4;
    }

    .news-card h3 a {
      color: #1e40af;
      text-decoration: none;
      transition: color 0.2s ease;
    }

    .news-card h3 a:hover {
      color: #1e3a8a;
    }

    .news-card p {
      color: #64748b;
      font-size: 0.95rem;
      line-height: 1.6;
    }

    .news-source {
      font-size: 0.85rem;
      color: #94a3b8;
      margin-top: 1rem;
      font-style: italic;
    }

    /* Side effects section */
    .side-effects-grid {
      display: grid;
      grid-template-columns: repeat(auto-fit, minmax(300px, 1fr));
      gap: 1.5rem;
      margin-top: 2rem;
    }

    .effect-card {
      background: #fff;
      border: 1px solid #e2e8f0;
      border-radius: 12px;
      padding: 1.5rem;
      box-shadow: 0 2px 8px rgba(0,0,0,0.05);
    }

    .effect-card h4 {
      color: #dc2626;
      font-size: 1.1rem;
      font-weight: 600;
      margin-bottom: 0.5rem;
    }

    .effect-card p {
      color: #64748b;
      font-size: 0.95rem;
      line-height: 1.6;
    }

    /* Image gallery */
    .image-gallery {
      display: grid;
      grid-template-columns: repeat(auto-fit, minmax(250px, 1fr));
      gap: 1.5rem;
      margin-top: 2rem;
    }

    .image-card {
      background: #fff;
      border-radius: 12px;
      overflow: hidden;
      box-shadow: 0 2px 8px rgba(0,0,0,0.05);
      transition: transform 0.2s ease;
    }

    .image-card:hover {
      transform: translateY(-2px);
    }

    .image-card img {
      width: 100%;
      height: 200px;
      object-fit: cover;
      display: block;
    }

    .image-card a {
      text-decoration: none;
      color: inherit;
      display: block;
      transition: transform 0.2s ease;
    }

    .image-card a:hover {
      transform: translateY(-2px);
    }

    .image-caption {
      padding: 1rem;
      background: #f8fafc;
      font-size: 0.9rem;
      color: #64748b;
      text-align: center;
    }

    /* About section */
    .about-content {
      background: #f8fafc;
      padding: 2rem;
      border-radius: 12px;
      border-left: 4px solid #1e40af;
    }

    .about-content p {
      margin-bottom: 1rem;
      font-size: 1rem;
      line-height: 1.7;
      color: #475569;
    }

    /* Contact form - optimized size */
    .contact-container {
      max-width: 500px;
      margin: 0 auto;
    }

    .form-group {
      margin-bottom: 1.5rem;
    }

    .form-group label {
      display: block;
      font-weight: 500;
      margin-bottom: 0.5rem;
      color: #374151;
    }

    .form-group input,
    .form-group textarea {
      width: 100%;
      padding: 0.75rem;
      border: 2px solid #e5e7eb;
      border-radius: 8px;
      font-size: 1rem;
      transition: border-color 0.2s ease;
      font-family: inherit;
    }

    .form-group input:focus,
    .form-group textarea:focus {
      outline: none;
      border-color: #1e40af;
      box-shadow: 0 0 0 3px rgba(30, 64, 175, 0.1);
    }

    .form-group textarea {
      resize: vertical;
      min-height: 100px;
    }

    .submit-btn {
      background: linear-gradient(135deg, #1e40af 0%, #1e3a8a 100%);
      color: #fff;
      padding: 0.875rem 2rem;
      border: none;
      border-radius: 8px;
      font-size: 1rem;
      font-weight: 600;
      cursor: pointer;
      transition: all 0.2s ease;
      width: 100%;
    }

    .submit-btn:hover {
      transform: translateY(-1px);
      box-shadow: 0 4px 12px rgba(30, 64, 175, 0.3);
    }

    /* Footer */
    /* CTA Section styles */
    .cta-section {
      background: #fff;
      padding: 3rem 0;
    }

    .cta-card {
      background: none;
      border-radius: 0;
      box-shadow: none;
      padding: 0;
      max-width: 1200px;
      width: 100%;
      margin: 0 auto;
      text-align: center;
    }

    .cta-card h2 {
      color: #1e293b;
      font-size: 3rem;
      font-weight: 800;
      margin-bottom: 2.2rem;
      text-align: center;
      position: relative;
      padding-bottom: 1.1rem;
      line-height: 1.18;
    }

    .cta-card h2::after {
      content: "";
      display: block;
      width: 100%;
      height: 4px;
      background: #1e40af;
      border-radius: 2px;
      margin: 1.1rem auto 0 auto;
      position: absolute;
      left: 0;
      bottom: 0;
    }

    .cta-card p {
      color: #334155;
      font-size: 1.125rem;
      margin-bottom: 2rem;
    }

    .cta-btn {
      display: inline-block;
      background: #dc2626;
      color: #fff;
      font-weight: 700;
      padding: 0.9rem 2.2rem;
      border-radius: 8px;
      font-size: 1.1rem;
      text-decoration: none;
      margin-bottom: 1.2rem;
      transition: background 0.2s;
    }
    .cta-btn:hover {
      background: #b91c1c;
    }

    .cta-note {
      color: #64748b;
      font-size: 0.98rem;
      margin-top: 0.5rem;
    }

    footer {
      background: #1e3a8a;
      color: #fff;
      padding: 3rem 2rem 2rem;
      margin-top: 4rem;
    }

    .footer-content {
      max-width: 1200px;
      margin: 0 auto;
      display: grid;
      grid-template-columns: repeat(auto-fit, minmax(250px, 1fr));
      gap: 2rem;
    }

    .footer-section h3 {
      font-size: 1.2rem;
      margin-bottom: 1rem;
      color: #bfdbfe;
    }

    .footer-section p,
    .footer-section a {
      color: #94a3b8;
      font-size: 0.9rem;
      line-height: 1.6;
      text-decoration: none;
    }

    .footer-section a:hover {
      color: #bfdbfe;
    }

    .footer-bottom {
      border-top: 1px solid #374151;
      margin-top: 2rem;
      padding-top: 1rem;
      text-align: center;
      color: #94a3b8;
      font-size: 0.85rem;
    }

    /* Additional styling */
    .section-intro {
      font-size: 1.1rem;
      color: #64748b;
      margin-bottom: 2rem;
      line-height: 1.7;
    }

    .highlight-box {
      background: linear-gradient(135deg, #dbeafe 0%, #bfdbfe 100%);
      border: 1px solid #93c5fd;
      border-radius: 12px;
      padding: 1.5rem;
      margin: 2rem 0;
    }

    .highlight-box h3 {
      color: #1e3a8a;
      margin-bottom: 0.5rem;
      font-size: 1.25rem;
    }

    .highlight-box p {
      color: #374151;
      margin: 0;
    }

    .timeline {
      position: relative;
      padding-left: 2rem;
    }

    .timeline::before {
      content: '';
      position: absolute;
      left: 0;
      top: 0;
      bottom: 0;
      width: 2px;
      background: #1e40af;
    }

    .timeline-item {
      position: relative;
      margin-bottom: 2rem;
      padding-left: 2rem;
    }

    .timeline-item::before {
      content: '';
      position: absolute;
      left: -0.5rem;
      top: 0.5rem;
      width: 1rem;
      height: 1rem;
      background: #1e40af;
      border-radius: 50%;
    }

    .timeline-date {
      font-weight: 600;
      color: #1e40af;
      margin-bottom: 0.5rem;
    }

    /* Modular content areas */
    .content-module {
      background: #fff;
      border: 1px solid #e2e8f0;
      border-radius: 12px;
      padding: 2rem;
      margin: 2rem 0;
      box-shadow: 0 2px 8px rgba(0,0,0,0.05);
    }

    .content-module h3 {
      color: #1e3a8a;
      font-size: 1.5rem;
      margin-bottom: 1rem;
    }

    .content-module p {
      color: #64748b;
      line-height: 1.7;
      margin-bottom: 1rem;
    }

    /* Responsive design */
    @media (max-width: 768px) {
      .header-container,
      .nav-container,
      main {
        padding-left: 1rem;
        padding-right: 1rem;
      }

      header h1 {
        font-size: 2rem;
      }

      .hero-section h2 {
        font-size: 2rem;
      }

      .news-grid {
        grid-template-columns: 1fr;
      }

      .side-effects-grid {
        grid-template-columns: 1fr;
      }

      .image-gallery {
        grid-template-columns: repeat(auto-fit, minmax(200px, 1fr));
      }

      .nav-container {
        flex-direction: column;
        gap: 0.5rem;
      }

      .stats-grid {
        grid-template-columns: repeat(auto-fit, minmax(200px, 1fr));
      }

      .footer-content {
        grid-template-columns: 1fr;
      }
    }

    @media (max-width: 480px) {
      header h1 {
        font-size: 1.75rem;
      }

      .hero-section h2 {
        font-size: 1.75rem;
      }

      .image-gallery {
        grid-template-columns: 1fr;
      }

      .stats-grid {
        grid-template-columns: 1fr;
      }
    }

    /* iPad specific optimizations */
    @media (min-width: 768px) and (max-width: 1024px) {
      .news-grid {
        grid-template-columns: repeat(2, 1fr);
      }

      .side-effects-grid {
        grid-template-columns: repeat(2, 1fr);
      }
    }
  </style>
</head>
<body>
  <!-- Fixed Phone Number Bar -->
  <div class="phone-bar">
    <a href="tel:800-553-8082">📞 FREE CASE EVALUATION: 800-553-8082</a>
  </div>

  <!-- Sticky Navigation Bar -->
  <div class="sticky-nav">
    <div class="nav-wrapper">
      <nav class="main-nav">
        <div class="nav-container">
          <div class="nav-links">
            <a href="#overview">Overview</a>
            <a href="#side-effects">Side Effects</a>
            <a href="#lawsuits">Lawsuits</a>
            <a href="#news">Latest News</a>
            <a href="#research">Research</a>
            <a href="#about">About Us</a>
            <a href="#contact">Contact</a>
          </div>
        </div>
      </nav>
    </div>
  </div>

  <!-- Floating Form -->
  <div class="floating-form" id="floatingForm">
    <div class="form-header">
      <h3>Quick Case Evaluation</h3>
    </div>
    <div class="form-content">
      <form action="case-evaluation.html" method="GET">
        <p class="form-intro">Find out if you qualify in 30 seconds</p>
        <div class="form-group">
          <select name="medication" required>
            <option value="">Which medication did you take?</option>
            <option value="ozempic">Ozempic</option>
            <option value="wegovy">Wegovy</option>
            <option value="mounjaro">Mounjaro</option>
            <option value="other">Other GLP-1</option>
          </select>
        </div>
        <div class="form-group">
          <select name="side_effect" required>
            <option value="">Did you experience side effects?</option>
            <option value="gastroparesis">Stomach Paralysis</option>
            <option value="pancreatitis">Pancreatitis</option>
            <option value="kidney">Kidney Problems</option>
            <option value="other">Other Issues</option>
          </select>
        </div>
        <button type="submit" class="floating-cta">Continue →</button>
      </form>
      <p class="form-note">Free Consultation • No Fee Unless We Win</p>
    </div>
  </div>

  <header class="main-header">

    <div class="hero-section">
      <div class="header-content">
        <div class="text-content">
          <h1>Have You Suffered Serious Side Effects from a GLP‑1 Drug?</h1>
          <p class="subtitle">Drugs like Ozempic, Wegovy, and Mounjaro have helped many manage diabetes and weight — but for some, the cost has been devastating. If you've experienced stomach paralysis (gastroparesis), intestinal blockage (ileus), persistent vomiting, or other serious complications, you may be entitled to legal compensation.</p>
          <div class="header-stats">
            <div class="stat-item">
              <span class="stat-number">1,100+</span>
              <span class="stat-label">MDL Lawsuits</span>
            </div>
            <div class="stat-item">
              <span class="stat-number">24,499+</span>
              <span class="stat-label">Reported Cases</span>
            </div>
            <div class="stat-item">
              <span class="stat-number">24/7</span>
              <span class="stat-label">Free Evaluation</span>
            </div>
          </div>
        </div>
        <div class="cta-container">
          <a href="case-evaluation.html" class="primary-cta">Check Your Eligibility Now</a>
          <p class="cta-note">Free Case Evaluation • No Fee Unless We Win</p>
          <div class="trust-badges">
            <span class="badge">Confidential Consultation</span>
            <span class="badge">Experienced Legal Team</span>
            <span class="badge">Nationwide Service</span>
          </div>
        </div>
      </div>
    </div>
  </header>

  <main>
    <!-- Hero Section -->
    <section class="hero-section">
      <h2>Serious Health Risks from GLP-1 Medications</h2>
      <p>Thousands of patients have experienced severe complications from Ozempic, Wegovy, Mounjaro, and other GLP-1 drugs. Our legal team is dedicated to helping victims seek compensation and justice.</p>
      <div class="hero-cta">
        <a href="case-evaluation.html" class="cta-button">Free Case Evaluation</a>
        <p class="cta-note">No fee unless we win your case. Free consultation available.</p>
      </div>
    </section>

    <!-- MDL Information Section -->
    <section id="mdl-info" class="mdl-section">
      <div class="mdl-container">
        <div class="mdl-header">
          <h2>MDL 3094: Nationwide Lawsuits Are Underway</h2>
          <p class="mdl-subtitle">In February 2024, a U.S. court created MDL No. 3094, consolidating over 1,100 lawsuits against Novo Nordisk and Eli Lilly, the makers of Ozempic, Wegovy, and Mounjaro.</p>
        </div>
        
        <div class="mdl-content">
          <div class="mdl-allegations">
            <h3>These lawsuits allege that:</h3>
            <ul>
              <li>The drugmakers failed to warn patients of the risk of serious gastrointestinal injuries</li>
              <li>Patients suffered long-term or permanent damage, including gastroparesis, bowel obstruction, pancreatitis, and more</li>
            </ul>
          </div>
          
          <div class="mdl-status">
            <p><strong>The cases are now moving forward in federal court under Judge Gene E.K. Pratter in Philadelphia.</strong> If you've been harmed, it's not too late to join.</p>
            <div class="warning-box">
              <p><strong>Each case remains individual.</strong> The sooner you act, the better your chances of preserving your rights and medical evidence.</p>
            </div>
          </div>
        </div>
      </div>
    </section>

    <!-- Statistics Section -->
    <section id="overview">
      <h2>Critical Statistics</h2>
      <p class="section-intro">Recent studies and reports reveal alarming statistics about GLP-1 medication side effects.</p>
      
      <div class="stats-grid">
        <div class="stat-card">
          <div class="stat-number">24,499</div>
          <div class="stat-label">Emergency Department Visits</div>
        </div>
        <div class="stat-card">
          <div class="stat-number">10+</div>
          <div class="stat-label">Deaths Reported</div>
        </div>
        <div class="stat-card">
          <div class="stat-number">100+</div>
          <div class="stat-label">Hospitalizations</div>
        </div>
        <div class="stat-card">
          <div class="stat-number">1,100+</div>
          <div class="stat-label">MDL Lawsuits</div>
        </div>
      </div>
    </section>

    <!-- Side Effects Section -->
    <section id="side-effects">
                <h2>Common Side Effects Named in Lawsuits</h2>
      <p class="section-intro">GLP-1 medications have been linked to numerous serious health complications that can be life-altering.</p>
      
      <div class="effects-categories">
        <div class="effect-category">
          <h3>Gastrointestinal Injuries</h3>
          <ul class="effect-list">
            <li>Gastroparesis (stomach paralysis)</li>
            <li>Persistent nausea or vomiting</li>
            <li>Intestinal blockage (ileus)</li>
            <li>Pancreatitis</li>
          </ul>
        </div>
        
        <div class="effect-category">
          <h3>Other Potential Complications</h3>
          <ul class="effect-list">
            <li>Vision loss</li>
            <li>Kidney dysfunction</li>
            <li>Suicidal ideation or mood changes</li>
            <li>Severe dehydration & malnutrition</li>
          </ul>
        </div>
      </div>
      
      <div class="side-effects-grid">
        <div class="effect-card">
          <h4><a href="gastroparesis.html" style="color: #dc2626; text-decoration: none;">Gastroparesis (Stomach Paralysis)</a></h4>
          <p>A condition where the stomach cannot empty properly, leading to severe nausea, vomiting, and abdominal pain. Many patients require surgical intervention.</p>
          <p><strong>Click for detailed information →</strong></p>
        </div>
        <div class="effect-card">
          <h4><a href="pancreatitis.html" style="color: #dc2626; text-decoration: none;">Pancreatitis</a></h4>
          <p>Inflammation of the pancreas that can be life-threatening. Studies show increased risk compared to other weight loss medications.</p>
          <p><strong>Click for detailed information →</strong></p>
        </div>
        <div class="effect-card">
          <h4><a href="gallbladder-disease.html" style="color: #dc2626; text-decoration: none;">Gallbladder Disease</a></h4>
          <p>Including gallstones and inflammation requiring surgical removal. Multiple patients have reported needing gallbladder removal after taking GLP-1 medications.</p>
          <p><strong>Click for detailed information →</strong></p>
        </div>
        <div class="effect-card">
          <h4><a href="bowel-obstruction.html" style="color: #dc2626; text-decoration: none;">Bowel Obstruction</a></h4>
          <p>Blockages preventing food or liquid from moving through the intestines, requiring emergency medical intervention.</p>
          <p><strong>Click for detailed information →</strong></p>
        </div>
        <div class="effect-card">
          <h4><a href="intestinal-tissue-death.html" style="color: #dc2626; text-decoration: none;">Intestinal Tissue Death</a></h4>
          <p>As reported in multiple cases, requiring surgical removal and permanent ileostomy. Some patients have lost parts of their large intestine.</p>
          <p><strong>Click for detailed information →</strong></p>
        </div>
        <div class="effect-card">
          <h4><a href="kidney-problems.html" style="color: #dc2626; text-decoration: none;">Kidney Problems</a></h4>
          <p>Including reduced kidney function and potential kidney damage, particularly concerning for long-term use.</p>
          <p><strong>Click for detailed information →</strong></p>
        </div>
        <div class="effect-card">
          <h4><a href="optic-nerve-damage.html" style="color: #dc2626; text-decoration: none;">Optic Nerve Damage</a></h4>
          <p>Potential vision impairment, as alleged in recent lawsuits against manufacturers.</p>
          <p><strong>Click for detailed information →</strong></p>
        </div>
        <div class="effect-card">
          <h4><a href="mental-health-issues.html" style="color: #dc2626; text-decoration: none;">Mental Health Issues</a></h4>
          <p>Including potential suicidal thoughts, as identified in European research and FDA monitoring.</p>
          <p><strong>Click for detailed information →</strong></p>
        </div>
      </div>
    </section>

    <!-- Lawsuits Timeline -->
    <section id="lawsuits">
      <h2>Legal Developments & Lawsuits</h2>
      <p class="section-intro">The legal landscape surrounding GLP-1 medications is rapidly evolving with multiple lawsuits filed across the country.</p>
      
      <div class="timeline">
        <div class="timeline-item">
          <div class="timeline-date">March 2024</div>
          <h4>Multiple Lawsuits Filed</h4>
          <p>Dozens of patients sued Eli Lilly and Novo Nordisk, claiming they suffered distressing digestive symptoms after taking the drugs. More than 60 lawsuits were centralized under a federal judge in Philadelphia.</p>
        </div>
        <div class="timeline-item">
          <div class="timeline-date">September 2024</div>
          <h4>Severe Case: Juanita Gantt</h4>
          <p>A 62-year-old patient was hospitalized after taking Wegovy and Ozempic. Parts of her large intestine died and needed to be removed. She now lives with a permanent ileostomy bag.</p>
        </div>
        <div class="timeline-item">
          <div class="timeline-date">October 2023</div>
          <h4>Study Links GLP-1 Drugs to Stomach Problems</h4>
          <p>Research published in JAMA found that people taking GLP-1 drugs had higher risk of pancreatitis, bowel obstruction, and gastroparesis compared to other weight loss medications.</p>
        </div>
        <div class="timeline-item">
          <div class="timeline-date">April 2025</div>
          <h4>25,000 Emergency Department Visits</h4>
          <p>Study revealed that an estimated 24,499 people visited emergency departments for adverse events related to semaglutide in just two years following its approval.</p>
        </div>
        <div class="timeline-item">
          <div class="timeline-date">July 2025</div>
          <h4>Optic Nerve Damage Lawsuit</h4>
          <p>A plaintiff from Illinois sued Novo Nordisk, claiming that Wegovy caused debilitating optic nerve damage, expanding litigation beyond gastrointestinal claims.</p>
        </div>
      </div>
    </section>

    <!-- News Section -->
    <section id="news">
      <h2>Latest News & Research</h2>
      <p class="section-intro">Stay informed about the latest developments and research regarding GLP-1 medications and their potential side effects.</p>
      
      <div class="news-grid">
        <div class="news-card">
          <h3><a href="news-detail.html" target="_blank">Poison control calls surge as GLP-1 drugs gain popularity</a></h3>
          <p>Pennsylvania and New Jersey poison control centers described a steep rise in calls related to GLP-1 weight-loss drugs. Exposures at New Jersey's center jumped from 29 cases in 2021 to 189 in 2024.</p>
          <div class="news-source">Source: WHYY News, May 2025</div>
        </div>

        <div class="news-card">
          <h3><a href="https://time.com/7130456/ozempic-side-effects-wegovy-mounjaro-gastroparesis-weight-loss/" target="_blank">Patients sue over alleged side effects of GLP-1 drugs</a></h3>
          <p>A TIME investigation highlights lawsuits filed by patients who experienced debilitating side effects while taking Ozempic, Wegovy, Mounjaro and other GLP-1 drugs.</p>
          <div class="news-source">Source: TIME Magazine, November 2024</div>
        </div>

        <div class="news-card">
          <h3><a href="https://www.uclahealth.org/news/article/ozempic-face-and-other-glp-1-side-effects" target="_blank">Ozempic face and other GLP-1 side effects</a></h3>
          <p>UCLA Health explains that rapid weight loss from GLP-1 drugs can cause cosmetic changes dubbed "Ozempic face" along with digestive issues.</p>
          <div class="news-source">Source: UCLA Health, May 2025</div>
        </div>
      </div>
    </section>

    <!-- Additional News Section -->
    <section id="research">
      <h2>Additional Research & Case Studies</h2>
      <p class="section-intro">Comprehensive research findings and detailed case studies documenting the impact of GLP-1 medications.</p>
      
      <div class="news-grid">
        <div class="news-card">
          <h3><a href="#" target="_blank">Study Links GLP-1 Drugs to Severe Stomach Problems</a></h3>
          <p>Research published in the Journal of the American Medical Association found that people taking GLP-1 drugs for weight loss had a higher risk of pancreatitis, bowel obstruction, and gastroparesis compared to those taking non-GLP-1 weight loss medications.</p>
          <div class="news-source">Source: NBC News, October 2023</div>
        </div>

        <div class="news-card">
          <h3><a href="#" target="_blank">Nearly 25,000 Emergency Department Visits Linked to Semaglutide</a></h3>
          <p>A study published in Annals of Internal Medicine revealed that an estimated 24,499 people visited emergency departments for adverse events related to semaglutide in just two years following its approval for weight loss.</p>
          <div class="news-source">Source: Healio Gastroenterology, April 2025</div>
        </div>

        <div class="news-card">
          <h3><a href="#" target="_blank">FDA Reports Multiple Deaths and Hospitalizations from Compounded Semaglutide</a></h3>
          <p>Approximately 10 deaths and 100 hospitalizations in the United States have been linked to use of off-brand, compounded semaglutide, according to the drug's manufacturer Novo Nordisk.</p>
          <div class="news-source">Source: Pharmacy Times, November 2024</div>
        </div>
      </div>
    </section>

    <!-- Modular Content Areas for Future Updates -->
    <section id="future-updates">
      <h2>Recent Developments</h2>
      <p class="section-intro">Latest updates and developments in GLP-1 litigation and research.</p>
      
      <div class="content-module">
        <h3>MDL Case Count Update - June 2025</h3>
        <p>There are currently 1,882 pending cases in the GLP-1 RA MDL (MDL 3094) in the Eastern District of Pennsylvania. For a litigation that only began in early 2024, that is a solid number, and filings have been steady.</p>
        <p>The docket includes almost all gastroparesis claims. There are an increasing number of vision loss lawsuits involving NAION, but this MDL does not cover those. The MDL consolidates claims involving Ozempic, Wegovy, Mounjaro, Rybelsus, and focuses on failure to warn of serious GI and vision-related side effects.</p>
        <p><strong>Key Developments:</strong></p>
        <ul>
          <li>Rule 702 Hearing on May 14, 2025 - Admissibility of expert causation testimony</li>
          <li>Defense focus on excluding expert opinions lacking gastric emptying tests</li>
          <li>Discovery currently limited to FDA label adequacy and warning content</li>
          <li>Plaintiffs targeting label inadequacy and misleading advertising</li>
        </ul>
      </div>

      <div class="content-module">
        <h3>NAION Claims Are Heating Up - June 2025</h3>
        <p>Twenty-one New Jersey plaintiffs who say they suffered permanent vision loss after taking Ozempic or Wegovy are seeking to consolidate their lawsuits into a multicounty litigation against Novo Nordisk. They are asking New Jersey state courts to coordinate the growing number of cases involving a rare and irreversible eye condition called nonarteritic anterior ischemic optic neuropathy, or NAION.</p>
        <p>These plaintiffs argue that centralization would streamline discovery, reduce inconsistent rulings, and make the litigation more manageable as filings continue to increase, the same arguments that got us a gastroparesis MDL.</p>
        <p><strong>Notable Developments:</strong></p>
        <ul>
          <li>NAION claims now generating more attention than gastroparesis lawsuits</li>
          <li>Permanent blindness presents particularly high-stakes form of injury</li>
          <li>More likely to motivate individual lawsuits, media coverage, and jury trials</li>
          <li>Scientific studies continue to examine causal link between GLP-1 receptor agonists and optic nerve damage</li>
        </ul>
      </div>

      <div class="content-module">
        <h3>Beyond Just NAION: Vision Loss Concerns - June 2025</h3>
        <p>A new study in JAMA Ophthalmology has added another entry to the growing ledger of concerns about Ozempic and Wegovy, with yet more concerns involving the loss of vision.</p>
        <p>Researchers from the University of Toronto found that patients taking semaglutide, the active ingredient in both drugs, were twice as likely to develop neovascular age-related macular degeneration (nAMD). This disease gradually destroys central vision and often leads to permanent impairment.</p>
        <p><strong>Study Details:</strong></p>
        <ul>
          <li>Looked at nearly 140,000 patients with type 2 diabetes from 2020 to 2023</li>
          <li>Risk was small in absolute terms, just over two in 1,000 for semaglutide users versus one in 1,000 for non-users</li>
          <li>Increase was real and statistically significant</li>
          <li>Researchers controlled for other known risk factors including kidney function, smoking, and use of insulin and metformin</li>
          <li>Biological plausibility: GLP-1 drugs alter vascular and inflammatory pathways directly implicated in macular degeneration</li>
        </ul>
      </div>

      <div class="content-module">
        <h3>New NAION Lawsuit Filed - June 2025</h3>
        <p>In a new lawsuit filed on Thursday in New Jersey Superior Court, a man from Woodbridge, New Jersey, alleges that his use of the weight-loss drug Wegovy caused him to suffer non-arteritic anterior ischemic optic neuropathy, resulting in permanent vision loss.</p>
        <p>The lawsuit claims that the drug's manufacturers failed to adequately warn consumers and healthcare providers about the risk of NAION. The plaintiff alleges that the company knew or should have known of the potential for Wegovy to cause optic nerve damage, yet continued to market the drug without proper safety disclosures.</p>
        <p>He is seeking compensatory and punitive damages for his injuries, ongoing medical treatment, and diminished quality of life.</p>
      </div>

      <div class="content-module">
        <h3>NAION Warning Momentum Building - June 2025</h3>
        <p>Momentum is building behind calls for the FDA to take action on Ozempic's potential vision risks. Several ophthalmologists and public health advocates are now urging the agency to require a black box warning on semaglutide drugs, including Ozempic, Wegovy, and Rybelsus, in light of mounting evidence linking them to nonarteritic anterior ischemic optic neuropathy (NAION).</p>
        <p>This comes after recent reports in JAMA Ophthalmology and a Danish registry study suggested a statistically significant association between semaglutide use and sudden vision loss events. The push for regulatory change is being amplified by attorneys involved in the New Jersey multicounty litigation effort, who argue that Novo Nordisk has long been aware of this potential risk but has failed to update its labeling accordingly.</p>
        <p>A black box warning would represent a major shift in how these drugs are regulated and could significantly impact their marketability and legal liability.</p>
      </div>

      <div class="content-module">
        <h3>Compounded Semaglutide Dangers - November 2024</h3>
        <p>Approximately 10 deaths and 100 hospitalizations in the United States have been linked to use of off-brand, compounded semaglutide (Ozempic), according to the drug's manufacturer Novo Nordisk. The report came after the company called on the FDA to prohibit compounding of semaglutide, citing significant safety concerns around the use of off-brand products.</p>
        <p><strong>Key Issues:</strong></p>
        <ul>
          <li>Novo Nordisk argued that semaglutide products should be placed on the Demonstrable Difficulties for Compounding (DDC) Lists</li>
          <li>Complexities associated with formulations, delivery mechanisms, dosage forms, achievement of bioavailability</li>
          <li>FDA had previously issued a letter stating there were over 350 cases of adverse events linked to use of compounded semaglutide</li>
          <li>Reports indicate dosing error, higher doses than approved by the FDA, and products containing salt forms instead of base forms</li>
          <li>Some facilities were selling semaglutide in combination with BPC-157, which has been prohibited by the FDA</li>
        </ul>
      </div>
    </section>

    <!-- Resources Section -->
    <section id="images">
      <h2>Resources & Information</h2>
      <p class="section-intro">Access important information and resources related to GLP-1 medications and their potential side effects.</p>
      
      <div class="image-gallery">
        <div class="image-card">
          <a href="ozempic-medication.html">
            <img src="ozempic.jpg" alt="Box of Ozempic / Wegovy weight‑loss drug (semaglutide)">
            <div class="image-caption">Ozempic/Wegovy Medication - Click for detailed information</div>
          </a>
        </div>
        <div class="image-card">
          <a href="gastrointestinal-effects.html">
            <img src="gastrointestinal-effects.jpg" alt="Medical illustration of gastrointestinal side effects and stomach discomfort">
            <div class="image-caption">Gastrointestinal Side Effects - Click for detailed information</div>
          </a>
        </div>
        <div class="image-card">
          <a href="legal-support-services.html">
            <img src="41aaabc7-c4b4-459a-a097-481045c12267.png" alt="Abstract illustration of legal assistance">
            <div class="image-caption">Legal Support Services - Click for detailed information</div>
          </a>
        </div>
      </div>

      <div class="content-module">
        <h3>Understanding Your Rights</h3>
        <p>If you or a loved one has experienced serious side effects from GLP-1 medications, you may have legal rights to compensation. Our legal team specializes in pharmaceutical litigation and can help you understand your options.</p>
        <ul>
          <li><strong>Free Case Evaluation:</strong> We offer confidential consultations to assess your case</li>
          <li><strong>No Upfront Costs:</strong> We work on a contingency fee basis - you only pay if we win</li>
          <li><strong>Nationwide Representation:</strong> We serve clients across the United States</li>
          <li><strong>Experienced Attorneys:</strong> Our team has successfully handled pharmaceutical litigation cases</li>
        </ul>
      </div>

      <div class="content-module">
        <h3>Common Questions About GLP-1 Lawsuits</h3>
        <p><strong>Q: What types of side effects qualify for a lawsuit?</strong></p>
        <p>A: Serious side effects that may qualify include gastroparesis, pancreatitis, gallbladder disease, bowel obstruction, intestinal tissue death, kidney problems, optic nerve damage, and mental health issues.</p>
        
        <p><strong>Q: How long do I have to file a lawsuit?</strong></p>
        <p>A: The time limit varies by state, typically 1-3 years from when you discovered or should have discovered your injury. It's important to consult with an attorney as soon as possible.</p>
        
        <p><strong>Q: What compensation might be available?</strong></p>
        <p>A: Potential compensation may include medical expenses, lost wages, pain and suffering, and punitive damages in some cases.</p>
        
        <p><strong>Q: Do I need to stop taking my medication?</strong></p>
        <p>A: You should consult with your healthcare provider before making any changes to your medication regimen. We can help you understand the risks and benefits.</p>
      </div>

      <div class="content-module">
        <h3>What You Can Do</h3>
        <div class="action-steps">
          <div class="action-step">
            <div class="step-content">
              <h4>Document your symptoms and diagnosis</h4>
              <p>Keep detailed records of all medical visits, symptoms, and treatments</p>
            </div>
          </div>
          <div class="action-step">
            <div class="step-content">
              <h4>Gather your medication history</h4>
              <p>Save all medication bottles, prescriptions, and medical records</p>
            </div>
          </div>
          <div class="action-step">
            <div class="step-content">
              <h4>Get a free legal evaluation</h4>
              <p>Understand your rights and potential compensation options</p>
            </div>
          </div>
        </div>
        <div class="urgent-notice">
          <p><strong>Don't wait.</strong> You may be eligible for compensation — but deadlines may apply.</p>
          <div class="eligibility-cta">
            <a href="case-evaluation.html" class="eligibility-button">Check Your Eligibility Now</a>
            <p class="cta-subtitle">Free Case Evaluation • No Fee Unless We Win</p>
          </div>
        </div>
      </div>

      <div class="content-module">
        <h3>Current Legal Developments</h3>
        <p>The legal landscape surrounding GLP-1 medications is rapidly evolving:</p>
        <ul>
          <li><strong>MDL Consolidation:</strong> Over 1,800 cases have been consolidated in federal court</li>
          <li><strong>New Jersey Litigation:</strong> 21 plaintiffs seeking multicounty litigation for vision loss claims</li>
          <li><strong>FDA Investigations:</strong> Ongoing monitoring of adverse event reports</li>
          <li><strong>Class Action Potential:</strong> Cases may be eligible for class action status</li>
        </ul>
      </div>

      <div class="content-module">
        <h3>Support Resources</h3>
        <p>If you're dealing with GLP-1 medication side effects, these resources may help:</p>
        <ul>
          <li><strong>Medical Support:</strong> Connect with specialists who understand GLP-1 complications</li>
          <li><strong>Patient Communities:</strong> Online support groups for those affected</li>
          <li><strong>Mental Health Resources:</strong> Counseling and support for depression and anxiety</li>
          <li><strong>Financial Assistance:</strong> Programs to help with medical expenses</li>
          <li><strong>Legal Guidance:</strong> Our team can help you understand your legal options</li>
        </ul>
      </div>
    </section>

    <!-- About Us Section -->
    <section id="about">
      <h2>About Our Legal Team</h2>
      <div class="about-content">
        <p>We are a North American law firm devoted to holding pharmaceutical companies accountable when their products cause harm. With extensive experience litigating cases involving dangerous drugs, our attorneys are committed to seeking justice for people who have suffered injuries or illnesses after taking GLP-1 medications.</p>
        <p>Our legal team understands the complex medical and regulatory issues surrounding weight‑loss and diabetes drugs. We collaborate with medical experts to investigate side effects and build strong cases. If you or a loved one has experienced severe nausea, vomiting, gastrointestinal problems or other complications after taking Ozempic, Wegovy, Mounjaro, Zepbound or similar medications, we are here to help.</p>
      </div> 

      <div class="highlight-box">
        <h3>Our Commitment</h3>
        <p>We provide compassionate guidance, thorough case evaluation and vigorous representation to help clients obtain compensation and support for their injuries and medical expenses.</p>
      </div>
    </section>

    <!-- Contact CTA Section -->
    <section id="contact" class="cta-section">
      <div class="cta-card">
        <h2>Get Your Free Case Evaluation</h2>
        <p>If you have been affected by GLP-1 medications, our legal team is ready to help. Take the first step towards justice today.</p>
        <a href="case-evaluation.html" class="cta-btn">Start Your Free Case Review →</a>
        <div class="cta-note">No fee unless we win your case. Confidential consultation available 24/7.</div>
      </div>
    </section>
  </main>

  <footer>
    <div class="footer-content">
      <div class="footer-section">
        <h3>Contact Information</h3>
        <p>📞 Free Case Evaluation: 800-553-8082</p>
        <p>📍 Serving clients nationwide</p>
        <p>⏰ Available 24/7 for consultations</p>
      </div>
      
      <div class="footer-section">
        <h3>Legal Services</h3>
        <p><a href="#">Product Liability</a></p>
        <p><a href="#">Mass Torts</a></p>
        <p><a href="#">Pharmaceutical Litigation</a></p>
        <p><a href="#">Personal Injury</a></p>
      </div>
      
      <div class="footer-section">
        <h3>Resources</h3>
        <p><a href="#">GLP-1 Side Effects</a></p>
        <p><a href="#">Legal Process</a></p>
        <p><a href="#">Frequently Asked Questions</a></p>
        <p><a href="#">Case Studies</a></p>
      </div>
      
      <div class="footer-section">
        <h3>Legal Information</h3>
        <p><a href="#">Disclaimer</a></p>
        <p><a href="#">Privacy Policy</a></p>
        <p><a href="#">Terms of Service</a></p>
        <p><a href="#">Attorney Advertising</a></p>
      </div>
    </div>
    
    <div class="footer-bottom">
      <p>&copy; 2025 GLP‑1 Side Effects Legal Support. All rights reserved. | Free consultation available.</p>
      <p>This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.</p>
      <p>Please do not include any confidential or sensitive information in a contact form. Submitting a contact form does not create an attorney-client relationship.</p>
    </div>
  </footer>

  <script>
    // Handle floating form visibility based on scroll position
    const floatingForm = document.getElementById('floatingForm');
    const seriousHealthSection = document.querySelector('#side-effects');
    
    function checkScrollPosition() {
      if (seriousHealthSection) {
        const sectionTop = seriousHealthSection.offsetTop;
        const scrollTop = window.pageYOffset || document.documentElement.scrollTop;
        const windowHeight = window.innerHeight;
        
        // Show floating form when user scrolls to Serious Health Risks section
        // Add some offset to make it appear slightly before the section
        if (scrollTop + windowHeight > sectionTop - 100) {
          floatingForm.classList.add('visible');
        } else {
          floatingForm.classList.remove('visible');
        }
      }
    }
    
    // Check on scroll
    window.addEventListener('scroll', checkScrollPosition);
    
    // Check on page load
    document.addEventListener('DOMContentLoaded', checkScrollPosition);

    // Handle form submissions
    document.querySelectorAll('form').forEach(form => {
      form.addEventListener('submit', function(e) {
        const submitBtn = form.querySelector('button[type="submit"]');
        if (submitBtn) {
          submitBtn.disabled = true;
          submitBtn.textContent = 'Submitting...';
        }
      });
    });
  </script>
</body>
</html>